Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A condensation aerosol for delivery of a drug selected from the group consisting of ephedrine and fenfluramine wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

2. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is formed at a rate greater than 10^9 particles per second.

3. (previously presented) The condensation aerosol according to Claim 2, wherein the condensation aerosol is formed at a rate greater than 10^{10} particles per second.

4.-6. (cancelled)

7. (previously presented) A method of producing a drug selected from the group consisting of ephedrine and fenfluramine in an aerosol form comprising:

a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and

b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

8. (previously presented) The method according to Claim 7, wherein the condensation aerosol is formed at a rate greater than 10^9 particles per second.

9. (previously presented) The method according to Claim 8, wherein the

condensation aerosol is formed at a rate greater than 10^{10} particles per second.

10.-12. (cancelled)

13. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

14. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

15. (currently amended) The condensation aerosol according to Claim 14, wherein the condensation aerosol is characterized by an MMAD of 0.2 ~~and~~ to 3 microns.

16. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

17. (previously presented) The condensation aerosol according to claim 16, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

18. (previously presented) The condensation aerosol according to Claim 1, wherein the solid support is a metal foil.

19. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is ephedrine.

20. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is fenfluramine.

21. (previously presented) The method according to Claim 7, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

22. (previously presented) The method according to Claim 7, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

23. (previously presented) The method according to Claim 22, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.

24. (previously presented) The method according to Claim 7, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

25. (previously presented) The method according to Claim 24, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

26. (previously presented) The method according to Claim 7, wherein the solid support is a metal foil.

27. (previously presented) The method according to Claim 7, wherein the drug is ephedrine.

28. (previously presented) The method according to Claim 7, wherein the drug is fenfluramine.

29. (previously presented) A condensation aerosol for delivery of ephedrine, wherein the condensation aerosol is formed by heating a thin layer containing ephedrine, on a solid support, to produce a vapor of ephedrine, and condensing the vapor to form a condensation aerosol characterized by less than 5% ephedrine degradation products by weight, and an MMAD of 0.2 to 3 microns.

30. (previously presented) A condensation aerosol for delivery of fenfluramine, wherein the condensation aerosol is formed by heating a thin layer containing fenfluramine, on a solid support, to produce a vapor of fenfluramine, and condensing the vapor to form a condensation aerosol characterized by less than 5% fenfluramine degradation products by

weight, and an MMAD of 0.2 to 3 microns.

31. (previously presented) A method of producing ephedrine in an aerosol form comprising:

a. heating a thin layer containing ephedrine, on a solid support, to produce a vapor of ephedrine, and

b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% ephedrine degradation products by weight, and an MMAD of 0.2 to 3 microns.

32. (previously presented) A method of producing fenfluramine in an aerosol form comprising:

a. heating a thin layer containing fenfluramine, on a solid support, to produce a vapor of fenfluramine, and

b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% fenfluramine degradation products by weight, and an MMAD of 0.2 to 3 microns.